» Articles » PMID: 20182682

[Rheopheresis for Recurrent Sudden Hearing Loss : Therapeutic Options for Patients Refractory to Infusion Therapy]

Overview
Journal HNO
Date 2010 Feb 26
PMID 20182682
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: For patients suffering from recurrent sudden hearing loss (SHL) that is refractory to infusion therapy, new therapeutic options must be established.

Patients And Methods: Patients suffering from recurrent and progressive SHL refractory to infusion therapy according to German guidelines were analysed retrospectively. After unsuccessful infusion therapy following the last onset of SHL, patients were treated with Rheopheresis twice. Hearing gain and recovery of speech discrimination were analysed.

Results: Twenty-five patients with a mean of 2.1+/-0.4 events of SHL within 30.0+/-21.6 months were examined. The patients' mean hearing loss before the first onset of SHL was 34 dB and was reduced by infusion therapy to 20 dB. With the second onset of SHL, hearing loss remained almost unchanged after infusion therapy. Patients showed a mean improvement of 20 dB after two consecutive Rheopheresis treatments. Forty percent showed complete remission of SHL, and a further 28% showed partial remission.

Conclusion: Rheopheresis can efficiently improve the hearing of patients with recurrent SHL refractory to infusion therapy.

Citing Articles

Randomized, placebo-controlled study on efficacy, safety and tolerability of drug-induced defibrinogenation for sudden sensorineural hearing loss: the lessons learned.

Weiss B, Spiegel J, Becker S, Strieth S, Olzowy B, Bertlich M Eur Arch Otorhinolaryngol. 2023; 280(9):4009-4018.

PMID: 36881166 PMC: 10382375. DOI: 10.1007/s00405-023-07896-z.


Rheopheresis in treatment of idiopathic sensorineural sudden hearing loss.

Kostal M, Drsata J, Blaha M, Lanska M, Chrobok V J Otolaryngol Head Neck Surg. 2017; 46(1):50.

PMID: 28662721 PMC: 5492286. DOI: 10.1186/s40463-017-0228-9.


[Pharmacotherapy of acute and chronic hearing loss].

Hesse G, Laubert A HNO. 2010; 58(10):990-8.

PMID: 20811867 DOI: 10.1007/s00106-010-2179-6.

References
1.
Rajagopalan L, Greeson J, Xia A, Liu H, Sturm A, Raphael R . Tuning of the outer hair cell motor by membrane cholesterol. J Biol Chem. 2007; 282(50):36659-70. PMC: 2679373. DOI: 10.1074/jbc.M705078200. View

2.
Klingel R, Mumme C, Fassbender T, Himmelsbach F, Altes U, Lotz J . Rheopheresis in patients with ischemic diabetic foot syndrome: results of an open label prospective pilot trial. Ther Apher Dial. 2003; 7(4):444-55. DOI: 10.1046/j.1526-0968.2003.00082.x. View

3.
Klemm E, Deutscher A, Mosges R . [A present investigation of the epidemiology in idiopathic sudden sensorineural hearing loss]. Laryngorhinootologie. 2009; 88(8):524-7. DOI: 10.1055/s-0028-1128133. View

4.
Guo Y, Zhang C, Du X, Nair U, Yoo T . Morphological and functional alterations of the cochlea in apolipoprotein E gene deficient mice. Hear Res. 2005; 208(1-2):54-67. DOI: 10.1016/j.heares.2005.05.010. View

5.
Fujimura T, Suzuki H, Shiomori T, Udaka T, Mori T . Hyperbaric oxygen and steroid therapy for idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol. 2007; 264(8):861-6. DOI: 10.1007/s00405-007-0272-6. View